Stroke: How safe and effective is the new thrombectomy system?

Mechanical thrombectomy (MT) is currently the standard treatment for the treatment of large vessel occlusion-acute ischemic stroke (LVO-AIS)

The 2019 guidelines of the American Heart/American Stroke Association and the 2019 guidelines of the European Stroke Organization/European Association for Minimally Invasive Neurotherapy agree that for the anterior circulation of the Alberta Stroke Project Early CT Score (ASPECTS) ≥6 that occurs within 6 hours after the onset of onset In patients with LVO-AIS, there is high-quality evidence to support the use of MT plus best medical management , rather than the best medical management alone

The Penumbra system (Penumbra Inc, Alameda) is a specially designed MT system that uses suction to remove blood clots

PROMISE (a prospective multicenter imaging study to evaluate chest pain), a three-dimensional (3D) randomized trial, and COMPASS ( cardiovascular outcome for those using anticoagulation strategies ) - provide additional clinical data supporting the performance of the Penumbra system

The American Heart/American Stroke Association guidelines cited the results of the COMPASS, ASTER, and 3D randomized trials, and recognized that frontline aspiration thrombectomy is not inferior to stent removal

In addition, several recent additions to the Penumbra system were not included in these previous trials

The primary safety endpoint is 90-day all-cause mortality

650 patients were enrolled (median age 70 years, 54.

The modified thrombolytic therapy for cerebral infarction has a rate of grade 2b to grade 3 of 87.

The Penumbra system is used in the real-world to perform front-line mechanical thrombectomy treatment for patients with large vessel occlusion-acute ischemic stroke.